BioAtla Inc.
Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer
About BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.
/ 
Frequently asked questions
To buy BioAtla Inc. stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for BioAtla Inc. by name or ticker, choose the number of shares, and place your order.
The ticker symbol for BioAtla Inc. is BCAB:xnas. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
BioAtla Inc. has its primary listing on NASDAQ. You can trade BioAtla Inc. with a Saxo account, alongside thousands of other stocks worldwide.
Yes, BioAtla Inc. is available to trade on SaxoInvestor and SaxoTraderGO. You can buy shares directly and include BioAtla Inc. as part of a broader investment portfolio. Explore our SaxoInvestor platform.
Learn more about investing and trading at Saxo’s educational content hub. Explore portfolio strategies, types of stocks, diversification, and valuation measures— so you can make more informed decisions when considering shares like BioAtla Inc..